RECENT NEWS 05 November 2014
2nd Preclinical Autoimmune Disease Proof of Concept for INV-17 ROR Gamma Inhibitor Portfolio Established in Rheumatoid Arthritis: Superior Therapeutic Efficacy Data to be Presented at the 2014 American College of Rheumatology Meeting
15 May 2014
INV-17 Preclinical Development in Multiple Autoimmune Diseases Profiled in SciBx Distillery: Therapeutics

INNOVIMMUNE is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune and ImmunoInflammatory Diseases.